Rocque GB, Williams CP, Ingram SA, et al. - Given that for patients with incurable, life‐limiting cancers such as metastatic breast cancer (MBC), time spent receiving cancer care may substantially be burdensome, researchers sought to report on the estimated time spent on health care in order to inform treatment‐related decision‐making. Assessing data from the following data sources: (a) direct observations from a time‐in‐motion quality improvement evaluation (process mapping); (b) cross‐sectional patient surveys; and (c) administrative claims, they identified that 7% to 10% of all days included within the initial 3 months of treatment are spent on health care, depending on treatment. Time spent traveling for care and on inpatient services had the greatest time contributions, hence time spent traveling and receiving inpatient care represented a substantial burden to patients with MBC. Modest contribution of time with providers to total care time was reported. Relative to patients receiving oral therapy, those receiving infusion/injection treatments spent more time in ambulatory care. Higher health care time was reported for patients receiving chemotherapeutic agents compared with those receiving hormonal agents.